Juno Therapeutics Resumes CAR T Cell Leukemia Clinical Trial

In a prior post we reported that Juno Therapeutics halted their acute lymphoblastic leukemia (ALL) CAR T Cell clinical trial due to patient deaths when they added a second chemotherapy (fludarabine) to the immunotherapy regimen plus cyclophosphamide. Less than a week later, the trial was cleared to be reopened by discontinuing the fludarabine and resuming the trial with cyclophosphamide and the CAR T Cell treatment alone.

According to CNBC news, the good news from the ROCKET trial improved their share price by 24 percent. The treatment is Juno's most advanced drug candidate.